Matricelf Ltd. Logo

Matricelf Ltd.

Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.

MTLF | TA

Overview

Corporate Details

ISIN(s):
IL0011767915
LEI:
Country:
Israel
Address:
3 Golda Meir Street, 7651713 Ness Zion
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Matricelf is a preclinical-stage biotechnology company specializing in personalized regenerative medicine. The company develops a proprietary platform for autologous 3D tissue engineering, which creates functional neural implants from a patient's own cells. The technology combines induced Pluripotent Stem Cells (iPSCs) with a personalized hydrogel derived from the patient's extracellular matrix (ECM). This approach is designed to create fully compatible, engineered tissues that promote regeneration without the risk of immune rejection. Matricelf's primary focus is on developing a one-time, curative solution for spinal cord injuries, with its platform also holding potential for treating other conditions such as stroke, traumatic brain injury, and myocardial infarction.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-09-08 20:40
Investor Presentation
COMPANY'S PRESENTATION
Hebrew (modern) 2.3 MB
2024-09-08 20:40
Pre-Annual General Meeting Information
COMPANY'S PRESENTATION
Russian 42.8 KB
2024-03-27 15:30
Investor Presentation
INVESTORS PRESENTATION
English 2.7 MB
2024-03-27 15:30
Pre-Annual General Meeting Information
INVESTORS PRESENTATION
Russian 43.3 KB
2023-02-14 16:31
Investor Presentation
Corporate Presentation - February2023
English 1.1 MB
2023-02-14 16:31
Regulatory News Service
Corporate Presentation - February2023
Russian 42.7 KB
2022-03-16 10:59
Investor Presentation
INVESTORS PRESENTATION
English 2.7 MB
2022-03-16 10:59
Pre-Annual General Meeting Information
INVESTORS PRESENTATION
Russian 41.6 KB
2021-06-17 18:14
Regulatory News Service
Opening of Trading On Sunday June 20, 2021, Appointment of a Market Maker
Hebrew (modern) 256.5 KB
2021-06-14 14:20
Regulatory News Service
Identifying Details of New Security: MATRICELF, MATRICELF.W1
Hebrew (modern) 177.2 KB

Automate Your Workflow. Get a real-time feed of all Matricelf Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Matricelf Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Matricelf Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America ADCT
Addex Therapeutics Ltd. Logo
Developing novel oral allosteric modulators to treat neurological disorders.
United States of America ADXN
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America ADIL

Talk to a Data Expert

Have a question? We'll get back to you promptly.